Emergent BioSolutions | EBS - Despesa De Juros Sobre A Dívida

Preço das Ações
7.93
Mudança Diária
-0.15 -1.86%
Mensal
-11.79%
Anual
70.17%
Q1 Previsão
7.84




Despesa De Juros Sobre A Dívida Alterar Data
Acadia Pharmaceuticals USD 0 4.12M 2024-09
Akebia Therapeutics 4.83M 359.32M 2025-12
ALKERMES USD 12.28M 7.63M 2025-12
Alnylam Pharmaceuticals USD 129.34M 84.94M 2025-12
Amarin USD 3K 5K 2024-12
ANI Pharmaceuticals USD 4.41M 316K 2025-12
BioMarin Pharmaceutical USD 2.78M 199K 2025-12
Coherus Biosciences USD 2.25M 76K 2025-12
Exelixis USD 23.4M 3.9M 2023-09
Glaxosmithkline GBP 177.95M 6.05M 2025-09
Heron Therapeutics USD 600K 100K 2024-12
Ionis Pharmaceuticals USD 18M 0 2025-12
Ironwood Pharmaceuticals USD 8.74M 506K 2024-12
Lexicon Pharmaceuticals USD 2.03M 124K 2025-12
Lonza CHF 84M 14M 2025-06
Merck USD 412M 85M 2025-12
Moderna USD 12.14B 12.13B 2025-09
Myriad Genetics USD 4.4M 600K 2025-12
Nektar Therapeutics USD 6.02M 420K 2024-09
Neurocrine Biosciences USD 1.1M 0 2024-03
Pacira USD 3.89M 387K 2025-12
Pfizer USD 711M 59M 2025-12
PTC Therapeutics USD 50.58M 2.59B 2025-12
Sanofi EUR -25M 252M 2025-12
Sarepta Therapeutics USD 7.56M 2.33M 2025-09
United Therapeutics USD 3.1M 100K 2025-12
Vanda Pharmaceuticals 601.14M 23.61M 2025-09
Xoma USD 3.4M 150K 2024-06